<DOC>
	<DOCNO>NCT01034176</DOCNO>
	<brief_summary>Our hypothesis 30 day oral levofloxacin ( FDA approve antibiotic ) patient persistent viremia ( BK virus find blood ) impair progress BK virus induce kidney damage significantly decrease eliminate BK virus blood .</brief_summary>
	<brief_title>BK Treatment Study</brief_title>
	<detailed_description />
	<mesh_term>Viremia</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<criteria>Living cadaveric kidney transplant recipient age 18 year BK viremia Female patient childbearing age pregnant adequate contraception maintain . Patients active infection , history malignancy/Posttransplant Lymphoproliferative Disease ( PTLD ) serologic positivity HIV . Patients evidence urinary tract obstruction cause allograft dysfunction , unless correct time enrollment . Patients clinical morphological evidence recurrence primary disease . Patients history allergic reaction quinolone antibiotic . Patients history prolong QT interval Patients recurrent hypoglycemic episode Patients history myasthenia gravis Patients take Thioridazine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>BK viremia</keyword>
	<keyword>kidney transplantation</keyword>
	<keyword>BK viremia kidney transplant recipient</keyword>
</DOC>